237 related articles for article (PubMed ID: 32718141)
1. [Immunotherapy and multidisciplinary approach to treatment in lung cancer].
Karadurmuş N; Kaya A; Göksel T; Yılmaz Ü; Tülek N
Tuberk Toraks; 2020 Mar; 68(1):66-75. PubMed ID: 32718141
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer: potential targets for immunotherapy.
Tartour E; Zitvogel L
Lancet Respir Med; 2013 Sep; 1(7):551-63. PubMed ID: 24461616
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Immunotherapy.
Bustamante-Alvarez JG; Owen DH
Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
7. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy E; Mezquita L; Remon J; Besse B
Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy and Immunotherapy for Lung Cancer.
Naylor EC; Desani JK; Chung PK
Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
Elias R; Morales J; Presley C
Curr Oncol Rep; 2017 Sep; 19(9):62. PubMed ID: 28755314
[TBL] [Abstract][Full Text] [Related]
10. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
12. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N; Santana-Davila R; Molina JR
Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
[TBL] [Abstract][Full Text] [Related]
13. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
[TBL] [Abstract][Full Text] [Related]
14. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
Ferrara R; Mezquita L; Auclin E; Chaput N; Besse B
Cancer Treat Rev; 2017 Nov; 60():60-68. PubMed ID: 28889085
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
17. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
18. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.
Friedlaender A; Banna GL; Buffoni L; Addeo A
Curr Oncol Rep; 2019 Nov; 21(12):107. PubMed ID: 31768759
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A; Hipp MM; Klinkhardt U; Früh M; Sebastian M; Weiss C; Pless M; Cathomas R; Hilbe W; Pall G; Wehler T; Alt J; Bischoff H; Geißler M; Griesinger F; Kallen KJ; Fotin-Mleczek M; Schröder A; Scheel B; Muth A; Seibel T; Stosnach C; Doener F; Hong HS; Koch SD; Gnad-Vogt U; Zippelius A
J Immunother Cancer; 2019 Feb; 7(1):38. PubMed ID: 30736848
[TBL] [Abstract][Full Text] [Related]
20. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
